About ITBMed
ITBMed is a company based in Stockholm (Sweden) founded in 2016 by David Sachs, Erik Berglund, and David Berglund. ITBMed has raised $87 million across 2 funding rounds from investors including 3E Bioventures Capital, Yonjin Capital and Binhai Venture Capital Investment Management. ITBMed offers products and services including Novel Therapy and Expanded Access Policy. ITBMed operates in a competitive market with competitors including Biogen, UCB, CareDx, Grifols and ALX Oncology, among others.
- Headquarter Stockholm, Sweden
- Founders David Sachs, Erik Berglund, David Berglund
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Itb-Med Ab
-
Annual Revenue
$3.22 K (USD)-53as on Dec 31, 2018
-
Net Profit
-$3.5 M (USD)-771as on Dec 31, 2018
-
EBITDA
Not available
-
Total Equity Funding
$87 M (USD)
in 2 rounds
-
Latest Funding Round
$20 M (USD), Series A
Dec 01, 2021
-
Investors
3E Bioventures Capital
& 3 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of ITBMed
ITBMed offers a comprehensive portfolio of products and services, including Novel Therapy and Expanded Access Policy.
Therapy induces tolerance in transplants to eliminate immunosuppression needs.
Policy provides access to therapies for eligible transplant patients.
People of ITBMed
Unlock access to complete
Unlock access to complete
Funding Insights of ITBMed
ITBMed has successfully raised a total of $87M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $20 million completed in December 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in ITBMed
ITBMed has secured backing from 4 investors, including venture fund, institutional, and angel investors. Prominent investors backing the company include 3E Bioventures Capital, Yonjin Capital and Binhai Venture Capital Investment Management.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Tech & Life Science focused early & growth stage VC firm investing in the US & China
|
Locked | Locked | Locked | |
|
Venture capital firm backed by Yongjin Group
|
Locked | Locked | Locked | |
|
Manages diversified investment portfolios across various asset classes.
|
Locked | Locked | Locked |
Investor details for ITBMed
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by ITBMed
Investment portfolio details for ITBMed
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - ITBMed
Detailed financials for ITBMed
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Itbmed Comparisons
Peer comparison for ITBMed
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of ITBMed
ITBMed operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Biogen, UCB, CareDx, Grifols and ALX Oncology, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapies for neurodegenerative and immunology disorders are developed.
|
|
| Locked | Locked | Locked |
Therapies for immunological and neurological disorders are developed.
|
|
| Locked | Locked | Locked |
Medical solutions for transplant patients are developed and provided.
|
|
| Locked | Locked | Locked |
Plasma-derived therapies are developed to treat multiple diseases.
|
|
| Locked | Locked | Locked |
ALX Oncology is focused on advancing cancer treatment therapies.
|
|
| Locked | Locked | Locked |
Small molecule protein degraders are developed for various disorders.
|
Detailed competitors of ITBMed
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Itbmed
Complete news archive for ITBMed
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about ITBMed
ITBMed was founded in 2016 and raised its 1st funding round 2 years after it was founded.
ITBMed is headquartered in Stockholm, Sweden.
Erik Berglund is the current CEO of ITBMed. They have also founded this company.
ITBMed is a funded company, having raised a total of $87M across 2 funding rounds to date.
Annual revenue of ITBMed is $3.22K as on Dec 31, 2018.
ITBMed was founded in 2016 in Stockholm, Sweden, within the biotechnology sector focused on immunology. Monoclonal antibodies are developed by the company to inhibit transplant rejections, with operations centered on a humanized IgG1K antibody called Siplizumab. This antibody targets CD2 receptors on T lymphocytes, natural killer cells, and thymocytes to block activation. The lead product is advancing through pivotal clinical trials for solid organ and bone marrow transplantation.
ITBMed's top competitors include CareDx, Alpine Immune Sciences and Generate Biomedicines.
ITBMed offers Novel Therapy and Expanded Access Policy.
ITBMed has 4 investors. Key investors include 3E Bioventures Capital, Yonjin Capital, Binhai Venture Capital Investment Management, and Pablo Legorreta.